News | Heart Failure | October 03, 2022

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

Presentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure with FUROSCIX (furosemide injection) at home 

Presentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure with FUROSCIX (furosemide injection) at home

October 3, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced two poster presentations, including a late breaker, at the Heart Failure Society of America (HFSA) 2022 Annual Meeting, which is being held September 30 – October 3, in Washington DC. 

“We are very pleased to have an opportunity to present scientific data at this year’s HFSA Annual Scientific Meeting, which is among the most important and well attended gatherings of heart failure experts each year,” stated John Tucker, chief executive officer of scPharmaceuticals. “The two presentations highlight the significant potential benefits – both to patients and payers – of an alternative approach to the management of congestion in patients with heart failure outside of the hospital. We believe FUROSCIX (furosemide injection), if approved, represents a potential new model for the treatment of congestion in patients with heart failure by allowing IV-equivalent diuresis at home, thus potentially reducing costly hospital admissions and readmissions.” 

“We are eagerly approaching our October 8 FUROSCIX PDUFA target action date, and, assuming FDA approval, are well prepared to initiate a robust commercial launch of FUROSCIX in 2022,” Tucker concluded. 

 

Details of the presentations are as follows: 

Title: 

Avoiding Treatment in Hospital with FUROSCIX to Manage Congestion in Heart Failure (AT HOME-HF) – A Pilot Study 

Poster #: 

LBA-007 (late breaking) 

Session: 

General Poster Viewing Session II 

Date: 

Saturday, October 1, 2022 

Time: 

12:45pm – 1:00pm EDT 

Location: 

Exhibit Hall ePoster Hub 

Summary: 

This poster describes the results of a Phase 2, multicenter, pilot study where 51 subjects presenting to a heart failure clinic with worsening congestion requiring augmented diuresis were randomized (2:1) to receive FUROSCIX or enhanced oral diuretics. 

Subjects who received FUROSCIX demonstrated augmented decongestion compared with patients receiving enhanced oral diuretics as demonstrated by: 

Improved diuresis as measured by a greater reduction in body weight from baseline at study day 3 (2.8 kg vs 0.8 kg, p=0.035); 

  • Improvement from baseline in mean 5-point dyspnea score at day 3 (-0.5 vs. 0.1, p=0.019); 
  • Greater number of patients with markedly or moderately better shortness of breath based on 7-point dyspnea at day 3 (44% vs 6%, p=0.006); 
  • Clinically relevant improvement from baseline in quality of life as measured by Kansas City Cardiomyopathy questionnaire – 12 (KCCQ-12) summary score at study days 7 and 30 of 8.9 points and 9.3 points, respectively; and 
  • An increase of 55.8 meters in the average six-minute walk distance at day 30 (36.7 vs -19.1 meters, p=.012). 

The win-ratio for the hierarchical endpoint of cardiovascular death, heart failure hospitalization, urgent ED/clinic visit for heart failure and the percentage change in NT-proBNP from baseline at day seven was 1.11 (95% Confidence Interval: 0.48-2.50) favoring the FUROSCIX group. 

During the 30-day study period, subjects in the FUROSCIX group spent an average of 23.2 days heart failure event free compared to 14.3 in subjects receiving enhanced oral diuretics. 

In the FUROSCIX group, 14.7% of subjects had a serum potassium level that was less than 3.5 mEq/L during the 30-day study and was managed effectively with oral potassium supplements. 

Conclusion: Subjects receiving subcutaneous FUROSCIX demonstrated augmented decongestion as evidenced by a greater reduction in body weight, better dyspnea scores, greater exercise capacity and improvement of health-related quality of life compared with patients receiving enhanced oral diuretics, or standard treatment in a phase 2, pilot study. The favorable results in the AT HOME-HF Pilot Study support conducting an adequately powered study. 

Title: 

Acute Decompensated Heart Failure: Examining Those with Brief Hospitalizations 

Poster #: 

291 

Session: 

General Poster Viewing Session IV 

Date: 

Sunday, October 2, 2022 

Time: 

12:30pm – 12:45pm EDT 

Location: 

Exhibit Hall ePoster Hub 

Summary: 

This poster describes a study that investigated the volume, length of stay (LOS) and patient characteristics of patients hospitalized for acute decompensated heart failure (ADHF) in the US using the multicenter National Inpatient Sample (NIS) representing approximately 20% of US acute care hospitals. Of the approximately 5 million discharges with any heart failure diagnosis code, 1.2 million patients had heart failure as the principal diagnosis code and approximately 43% of such patients had a LOS of less than 3 days (SLOS) with the average LOS being 2.2 days. Compared to patients with LOS greater than 3 days (LLOS), SLOS patients were less likely to require mechanical ventilation (2.8% vs 0.7%), dialysis (2.9% vs 0.4%) and undergo diagnostic procedures (70.4% vs 48.4%). SLOS patients were more likely to have a routine discharge to home (61.8% vs 39.7%) 

Conclusion: An alternative outpatient heart failure management may allow many patients to avoid the need for short hospitalizations with its potential complications and healthcare costs. 

For more information: www.scPharmaceuticals.com 


Related Content

News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
News | Heart Failure

February 22, 2024 — Wake Forest University School of Medicine, the academic core of Advocate Health, is expanding ...

Home February 22, 2024
Home
News | Heart Failure

February 15, 2024 — Canary Medical, a medical data company focused on the development and commercialization of its ...

Home February 15, 2024
Home
News | Heart Failure

February 12, 2023 — A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully ...

Home February 12, 2024
Home
News | Heart Failure

January 30, 2024 — Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a single ...

Home January 30, 2024
Home
Subscribe Now